Detalhe da pesquisa
1.
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Nature
; 615(7954): 920-924, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36922593
2.
MEN1 mutations mediate clinical resistance to menin inhibition.
Nature
; 615(7954): 913-919, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36922589
3.
Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis.
Nature
; 574(7777): 273-277, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31578525
4.
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
Blood
; 140(12): 1345-1377, 2022 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35797463
5.
Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies.
Haematologica
; 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38450530
6.
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
Nature
; 559(7712): 125-129, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29950729
7.
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Cancer
; 129(15): 2308-2320, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37078412
8.
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Blood
; 137(13): 1792-1803, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33024987
9.
Routine clinical parameters and laboratory testing predict therapy-related myeloid neoplasms after treatment for breast cancer.
Haematologica
; 108(1): 161-170, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35770528
10.
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(5): 503-513, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37156478
11.
Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia.
Am J Hematol
; 98(12): 1869-1876, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37688521
12.
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.
Am J Hematol
; 98(1): 79-89, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36251406
13.
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Blood
; 135(7): 463-471, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31841594
14.
Atypical pathogens presenting with pulmonary consolidations detected by cell-free DNA next-generation sequencing in patients with hematologic malignancies.
Infect Dis Clin Pract (Baltim Md)
; 30(2)2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35586753
15.
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
Lancet Oncol
; 22(11): 1597-1608, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34672961
16.
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
N Engl J Med
; 378(25): 2386-2398, 2018 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29860938
17.
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Blood
; 133(7): 676-687, 2019 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30510081
18.
Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia.
Am J Hematol
; 96(6): 735-746, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33625753
19.
IDH2 inhibition in AML.
Blood
; 141(2): 124-125, 2023 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36633887
20.
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.
Blood
; 132(11): 1125-1133, 2018 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30045838